Andrew B. McElroy
CEO Eligochem Ltd.
Title: Polar Drugs
Dr McElroy graduated from Churchill College Cambridge in 1980 with a first class degree in Natural Sciences and completed a PhD in synthetic organic chemistry before joining Glaxo as a medicinal chemist in 1983. He spent seven years at the Ware and Greenford sites working on CNS targets and then three years at the Research Triangle Park in North Carolina as the lead chemist on Cardiovascular projects.Andy joined Pfizer in Sandwich in 1993 as a manager in the Medicinal Chemistry department. He became Therapeutic Area Lead for Cardiovascular and Neurodegeneration Research, and later on Tissue Repair managing a portfolio of projects up to First in Human. Andy held leadership roles in chemistry technologies over many years and held global responsibilities for coordinating the continuous improvement of research processes and workflow. At the start of 2009 he became site lead at the Sandwich Site for External Research Solutions group, leading a multidisciplinary team focusing on optimizing external research and in 2011 co-founded TRN the Research Network Ltd. (www.trn.net) and in 2012 Eligochem Limited (www.eligocehem.com).
This presentation will describe a technology for the systematic design of polar compounds with atypical absorption properties and the application of this technology in a range of drug discovery settings enabling the exploration of novel chemical space with unique advantages.